Anthony Langone
YOU?
Author Swipe
View article: Twelve‐month kidney and liver outcomes of kidney transplantation from Hepatitis C Viremic deceased donors to aviremic recipients
Twelve‐month kidney and liver outcomes of kidney transplantation from Hepatitis C Viremic deceased donors to aviremic recipients Open
Introduction Utilization of hepatitis C viremic (HCV+) deceased donor kidneys (DDKT) for aviremic recipients increases opportunities for transplantation with excellent short‐term outcomes. Our primary aim was to understand longer‐term outc…
View article: Emphysematous gastritis due to <i>Sarcina ventriculi</i> infection in an immunocompromised adult
Emphysematous gastritis due to <i>Sarcina ventriculi</i> infection in an immunocompromised adult Open
The authors declare no conflict of interest. Data sharing is not applicable to this article as no new data were created or analyzed in this study.
View article: Monoclonal antibody treatment for COVID‐19 in solid organ transplant recipients
Monoclonal antibody treatment for COVID‐19 in solid organ transplant recipients Open
Solid organ transplant (SOT) recipients are at high risk for severe coronavirus disease 2019 (COVID‐19). Studies suggest that early intervention with monoclonal antibody (MAB) treatment directed against the SARS‐CoV‐2 spike protein may red…
View article: Kidney Transplantation From Hepatitis C Viremic Deceased Donors to Aviremic Recipients in a Real-world Setting
Kidney Transplantation From Hepatitis C Viremic Deceased Donors to Aviremic Recipients in a Real-world Setting Open
Background. Transplantation of hepatitis C viremic (HCV+) deceased donor kidney transplants (DDKT) into aviremic (HCV–) recipients is a strategy to increase organ utilization. However, there are concerns around inferior recipient outcomes …
View article: How Should We Manage Renal Transplant Patients with Failed Allografts Who Return to Dialysis?
How Should We Manage Renal Transplant Patients with Failed Allografts Who Return to Dialysis? Open
Patients with failing renal allografts often progress to end-stage renal disease, unlike transplant-naive chronic kidney disease patients, in an accelerated and unpredictable manner. The variability of this population renders decisions reg…
View article: Development of a collaborative pharmacy practice agreement to improve efficiency and management of prescribing in a renal transplant clinic
Development of a collaborative pharmacy practice agreement to improve efficiency and management of prescribing in a renal transplant clinic Open
Background: Post-transplant patients require complex medication regimens to ensure the survival of the transplanted organ and patient overall well-being. These regimens are frequently adjusted, initiated, or discontinued after transplantat…
View article: Unexpected Race and Ethnicity Differences in the US National Veterans Affairs Kidney Transplant Program
Unexpected Race and Ethnicity Differences in the US National Veterans Affairs Kidney Transplant Program Open
Background. Racial/ethnic minorities have lower rates of deceased kidney transplantation (DDKT) and living donor kidney transplantation (LDKT) in the United States. We examined whether social determinants of health (eg, demographics, cultu…
View article: Donor-derived Cell-free DNA Identifies Antibody-mediated Rejection in Donor Specific Antibody Positive Kidney Transplant Recipients
Donor-derived Cell-free DNA Identifies Antibody-mediated Rejection in Donor Specific Antibody Positive Kidney Transplant Recipients Open
Background Elevated levels of donor-derived cell-free DNA (dd-cfDNA) in the plasma of renal allograft recipients indicates organ injury and an increased probability of active rejection. Donor-specific antibodies (DSA) to HLA antigens are a…
View article: Biological Variation of Donor-Derived Cell-Free DNA in Renal Transplant Recipients: Clinical Implications
Biological Variation of Donor-Derived Cell-Free DNA in Renal Transplant Recipients: Clinical Implications Open
Background Previous studies have demonstrated that donor-derived cell-free DNA (dd-cfDNA) found in circulating blood of transplant recipients may serve as a noninvasive biomarker of allograft rejection. To better interpret the clinical mea…
View article: Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis
Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis Open
Light chain amyloidosis (AL) results in tissue deposition of misfolded proteins, causing organ dysfunction. In an era of modern therapies, such as bortezomib, reassessment of the benefit of autologous hematopoietic cell transplantation (AH…
View article: Cell-Free DNA and Active Rejection in Kidney Allografts
Cell-Free DNA and Active Rejection in Kidney Allografts Open
Histologic analysis of the allograft biopsy specimen is the standard method used to differentiate rejection from other injury in kidney transplants. Donor-derived cell-free DNA (dd-cfDNA) is a noninvasive test of allograft injury that may …
View article: IgA-Dominant Acute Postinfectious Glomerulonephritis Presenting as Acute Renal Failure in a Kidney Transplant Recipient
IgA-Dominant Acute Postinfectious Glomerulonephritis Presenting as Acute Renal Failure in a Kidney Transplant Recipient Open
IgA-dominant acute postinfectious glomerulonephritis (APIGN) is a morphologic variant of APIGN in which IgA is the dominant or co-dominant Ig found in glomerular immune deposits. It is a rare disease and, to our knowledge, has not been pre…
View article: Has the Department of Veterans Affairs Found a Way to Avoid Racial Disparities in the Evaluation Process for Kidney Transplantation?
Has the Department of Veterans Affairs Found a Way to Avoid Racial Disparities in the Evaluation Process for Kidney Transplantation? Open
Our results indicate that the VA National Transplant System did not exhibit the racial disparities in evaluation for KT as have been found in non-VA transplant centers.
View article: Autologous Hematopoietic Cell Transplant (AHCT) Offers Prolonged Progression Free and Overall Survival in Patients with Light Chain Amyloidosis (AL) Compared with Chemotherapy Alone
Autologous Hematopoietic Cell Transplant (AHCT) Offers Prolonged Progression Free and Overall Survival in Patients with Light Chain Amyloidosis (AL) Compared with Chemotherapy Alone Open
AL results in tissue deposition of misfolded proteins causing organ dysfunction. As new therapies for AL become available, reassessment of the role of AHCT is necessary. Hematological responses (HR) have been well studied; however the impa…
View article: Drugs in development for prophylaxis of rejection in kidney-transplant recipients
Drugs in development for prophylaxis of rejection in kidney-transplant recipients Open
Transplantation is the preferred treatment option for individuals with end-stage renal disease. Individuals who undergo transplantation must chronically be maintained on an immunosuppression regimen for rejection prophylaxis to help ensure…
View article: Switching <scp>ST</scp>udy of Kidney TRansplant <scp>PA</scp>tients with Tremor to <scp>LCP</scp>‐TacrO (<scp>STRATO</scp>): an open‐label, multicenter, prospective phase 3b study
Switching <span>ST</span>udy of Kidney TRansplant <span>PA</span>tients with Tremor to <span>LCP</span>‐TacrO (<span>STRATO</span>): an open‐label, multicenter, prospective phase 3b study Open
Tremor is a common side effect of tacrolimus correlated with peak‐dose drug concentration. LCPT , a novel, once‐daily, extended‐release formulation of tacrolimus, has a reduced C max with comparable AUC exposure, requiring a ~30% dose redu…